A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors
Givastomig（一种 CLDN18.2 和 4-1BB 双特异性抗体）作为单药疗法治疗 CLDN18.2 阳性晚期或转移性实体瘤患者的首次人体研究
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-4280
Ku, Geoffrey; Shen, Lin; Dayyani, Farshid; Kratz, Jeremy; Liang, Xinjun; Liu, Funan; Wang, Zhenning; Feller, Laura; Girda, Eugenia; Pan, Hongming; Kim, Sunnie; Deng, Yanhong; Deng, Ting; Liu, Tianshu; Powderly, John; Spencer, Kristen; Schneider, Reva; Berlin, Jordan; Xu, Claire Cong; Ahlers, Christoph M; Liu, Xuejun; Chung, Jou-Ku; Sabbatini, Peter; Park, Jinyoung; Lim, Yangmi; Jeon, Juyeun; Meng, Yuan; Klempner, Samuel J
